Open access
Open access
Powered by Google Translator Translator

Oncology – Skin

RCT: Sirolimus plus prednisolone vs. sirolimus monotherapy for kaposiform hemangioendothelioma.

18 Jan, 2022 | 09:08h | UTC

Sirolimus plus prednisolone vs sirolimus monotherapy for kaposiform hemangioendothelioma: a randomized clinical trial – Blood (link to abstract – $ for full-text)

 


RCT: In patients with untreated advanced melanoma, treatment with Relatlimab plus Nivolumab was associated with increased median progression-free survival compared with Nivolumab alone (10.1 months vs. 4.6 months).

12 Jan, 2022 | 08:43h | UTC

Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma – New England Journal of Medicine (link to abstract – $ for full-text)

Commentary: Relatlimab plus nivolumab improves progression-free survival in metastatic melanoma – University of Texas M. D. Anderson Cancer Center

 

Commentary on Twitter

 


RCT: Long-term outcomes with Nivolumab plus Ipilimumab or Nivolumab alone vs. Ipilimumab in patients with advanced melanoma.

5 Dec, 2021 | 23:07h | UTC

Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma – Journal of Clinical Oncology

Editorial: CheckMate-067: Raising the Bar for the Next Decade in Oncology – Journal of Clinical Oncology

Original Study: #ESMO19 – Randomized Trial: Improved Overall Survival at 5 Years with Combined Immunotherapy for Advanced Melanoma

 


Guideline on Cutaneous Angiosarcomas – Update 2021.

26 Nov, 2021 | 10:00h | UTC

S1-Guideline Cutaneous Angiosarcomas – Update 2021 – Journal of the German Society of Dermatology

 


Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab.

16 Nov, 2021 | 08:14h | UTC

Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study – The Lancet Oncology (link to abstract – $ for full-text)

Commentary: Combination immunotherapy improves survival for patients with asymptomatic melanoma brain metastases – The University of Texas MD Anderson Cancer Center

Original Study: Study: Combination Immunotherapy for Melanoma Brain Metastases

Related: #ESMO19 – Randomized Trial: Improved Overall Survival at 5 Years with Combined Immunotherapy for Advanced Melanoma

 


RCT: Overall survival benefit with Tebentafusp in metastatic uveal melanoma.

28 Sep, 2021 | 09:03h | UTC

Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma – New England Journal of Medicine

 

Commentary on Twitter

 


Viewpoint: Sentinel lymph node biopsy in cutaneous melanoma—where do we stand?

22 Aug, 2021 | 22:16h | UTC

Sentinel Lymph Node Biopsy in Cutaneous Melanoma—Where Do We Stand? – JAMA Dermatology (free for a limited period)

 


US Report: Death rates are declining for many common cancers, including lung cancer and melanoma.

15 Jul, 2021 | 09:11h | UTC

Report: Annual Report to the Nation on the Status of Cancer, Part 1: National Cancer Statistics – JNCI: Journal of the National Cancer Institute

News release: Annual Report to the Nation: Rapid decrease in lung cancer and melanoma deaths lead overall continued decline in cancer death rate – National Cancer Institute

Commentaries: Death rates are declining for many common cancers in the U.S., report finds – STAT AND Annual report to the nation: Rapid decrease in lung cancer and melanoma deaths – American Cancer Society

 


Viewpoint | Active surveillance as a management option for low-risk basal cell carcinoma.

15 Jun, 2021 | 08:49h | UTC

Active Surveillance as a Management Option for Low-risk Basal Cell Carcinoma – JAMA Internal Medicine

 


An epidemic of overdiagnosis: Melanoma diagnoses sky rocket

20 Jan, 2021 | 01:30h | UTC

An epidemic of overdiagnosis: Melanoma diagnoses sky rocket – Brigham and Women’s Hospital AND Does Screening for Skin Cancer Result in Melanoma Overdiagnosis? – Univadis

Original study: The Rapid Rise in Cutaneous Melanoma Diagnoses ($)

Related: Overdiagnosis: what it is and what it isn’t – BMJ Evidence Based Medicine (free) AND Overdiagnosis across medical disciplines: a scoping review – The BMJ Open (free) AND Too much medical care: bad for you, bad for health care systems – STAT News (free) AND Screening: How overdiagnosis and other harms can undermine the benefits – Health News Review (free) AND Overdiagnosis: causes and consequences in primary health care – Canadian Family Physician (free) AND Five warning signs of overdiagnosis – The Conversation (free) AND What is overdiagnosed cancer? And why does it matter? – Croakey (free) AND Blame rising cancer overdiagnosis on ‘irrational exuberance’ for early detection – STAT (free) AND Preventing overdiagnosis and the harms of too much sport and exercise medicine – British Journal of Sports Medicine (free)

 


Stay Updated in Your Specialty

No spam, just news.